Thiocolchicoside is a centrally-acting muscle relaxant with potent anti-inflammatory and analgesic properties. It is a semi-synthetic derivative of colchicoside, where the acetyl group is replaced by a thiomethyl group, enhancing its muscle relaxant activity and reducing gastrointestinal side effects. It acts as a competitive antagonist at the GABA-A receptor and glycine receptor sites in the spinal cord and brainstem, leading to muscle relaxation. It is widely used in the Indian clinical setting for acute painful musculoskeletal conditions.
Adult: 4 mg twice daily (morning and evening). Maximum duration of treatment should not exceed 7-10 days.
Note: To be taken after food with a full glass of water to minimize gastric irritation. The tablet should be swallowed whole, not chewed or crushed. Evening dose may cause drowsiness.
Thiocolchicoside exerts its muscle relaxant effect primarily by competitively blocking the strychnine-sensitive glycine receptors and acting as a GABA-A receptor antagonist in the spinal cord and brainstem interneurons. This blockade inhibits the polysynaptic reflexes responsible for increased muscle tone and spasticity. It also possesses peripheral anti-inflammatory activity by inhibiting prostaglandin synthesis and leukocyte migration.
Pregnancy: CONTRANDICATED, especially in first trimester. Animal studies have shown teratogenic effects (skeletal abnormalities). It may cause fetal harm. Category D as per some references.
Driving: Patients should be warned that thiocolchicoside can cause dizziness and drowsiness, impairing the ability to drive or operate machinery. Avoid such activities until individual response is known.
| CNS Depressants (Alcohol, Benzodiazepines, Opioids) | Additive CNS depression, increased risk of sedation, dizziness, and impaired coordination. | Major |
| Other Muscle Relaxants (Baclofen, Tizanidine) | Enhanced muscle relaxation, increased risk of weakness and respiratory depression. | Major |
| Strong CYP3A4 Inhibitors (Ketoconazole, Clarithromycin, Ritonavir) | May increase thiocolchicoside plasma levels, increasing risk of toxicity. | Moderate |
| NSAIDs (Diclofenac, Aceclofenac, Ibuprofen) | Increased risk of gastrointestinal bleeding/ulceration. Often used together but monitor for GI side effects. | Moderate |
| Anticholinergics (Atropine, Oxybutynin) | Increased risk of dry mouth, urinary retention, and constipation. | Moderate |